echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Sanofi and C4X reached a partnership to enter the IL-17A inhibitor market

    Sanofi and C4X reached a partnership to enter the IL-17A inhibitor market

    • Last Update: 2021-07-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

           On April 12, C4X Discovery Holdings plc announced that it has signed a global exclusive license agreement with Sanofi for its preclinical oral IL-17A inhibitor
    .
    According to the agreement, C4XD will receive an advance payment of 7 million euros and a potential development, regulatory and commercialization milestone payment of up to 407 million euros

    .
    This transaction means that Sanofi will enter the IL-17A inhibitor market

    .

           IL-17A belongs to the interleukin-17 (IL-17) family and plays an important role in promoting the inflammatory state in the autoimmune response of diseases such as psoriasis, psoriatic arthritis and ankylosing spondylitis (AS)
    .
    IL-17 was first discovered by researchers in 1993, and subsequent studies found that it plays an important role in host defense, autoimmune disease pathogenesis, and tumors, and has gradually become a research hotspot in medicine and immunology

    .

           There are six subtypes of IL-17 family ligands: IL-17A, IL-17B, IL-17C, IL-17 D, IL-17E (also called IL-25) and IL-17F
    .
    Among them, IL-17A and IL-17F have high homology (55%) and are often co-expressed

    .
    IL-17 receptors include IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE

    .
    IL-17 ligand produces organ-specific pro-inflammatory or anti-inflammatory response through its corresponding receptor

    .

           At present, 4 macromolecular biopharmaceuticals targeting IL-17/IL-17R have been approved globally, namely Novartis’ Cosentyx (Secukinumab), Eli Lilly’s Taltz (Ixekizumab), Siliq/Lumicef (Brodalumab, Broliumab) of Kylin and Efleira (Netakimab) of Biocad
    .
    In addition, UCB has also submitted a biological product license application for the target IL-17A/IL-17F monoclonal antibody bimekizumab

    .

           Cosentyx is the first IL-17A monoclonal antibody approved globally.
    It was first approved in Japan in December 2014, and was subsequently approved in Europe and the United States in January 2015.
    It has been approved for the treatment of adults and 6 to 18 years old.
    Moderate to severe plaque psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and radiology-negative axial spondyloarthritis (nr-axSpA)

    .

           Taltz is the second IL-17A monoclonal antibody approved by the FDA after Cosentyx.
    It was first approved in the United States in March 2016.
    It is currently approved for the treatment of adults and 6 to 18 years of age with moderate to severe PsO, PsA, AS and nr-axSpA

    .

           Siliq (brolizumab, also called bedaluzumab) is the third FDA-approved monoclonal antibody against the IL-17 pathway.
    Its target is IL-17RA.
    It was approved in Japan in July 2016.
    , The trade name is Lumicef, which was approved in the United States in February 2017, the trade name is Siliq, and it was approved in Europe in July 2017, the trade name is Kyntheum, and the indication is PsO

    .
    The drug was first developed by Amgen, and then AstraZeneca and Kyowa Fermentation Kirin Co.
    , Ltd.
    obtained its research and development authorization, and Kyowa Fermentation has the exclusive rights of the drug in Japan and some other Asian countries

    .
    In July 2016, AstraZeneca exclusively authorized the development and commercialization rights of the drug in the European market to LE0 Pharma.
    In September 2015, AstraZeneca authorized the development and commercialization rights of the drug in other markets outside the aforementioned countries and regions.
    To Valeant

    .
    It is worth noting that the drug has a suicidal tendency

    .

           Netakimab (BCD-085) was approved in Russia in May 2019 for the treatment of moderate to severe plaque psoriasis under the trade name Efleira
    .
    In September 2019, SPH PROJECT BIOCAD Limited (hereinafter referred to as SPH PB), a wholly-owned subsidiary of Shanghai Pharmaceuticals, signed an agreement with Biocad to establish a joint venture company to introduce 6 products including the drug into the country

    .

           These four drugs are all administered by subcutaneous injection.
    Cosentyx and Taltz were launched earlier, with the most approved indications, and the market performance is relatively bright.
    Sales have increased year by year since they were launched.
    Cosentyx has been on the market for two consecutive years since 2019.
    Become Novartis' highest-selling drug

    .

           In view of the market potential of IL-17 pathway-targeted drugs, many domestic companies have begun to deploy.
    Among them, Hengrui Pharmaceutical's Vunakizumab and Zhixiang (Shanghai) Pharmaceutical have made rapid progress and are in phase III clinical trials

    .

           In addition, on May 15, 2020, Chuangsheng Biotechnology introduced the IL-17-like antibody ABY-035 from Affibody at a price of US$225 million in May last year
    .
    However, it is worth mentioning that the drugs that have been on the market and under development that target the IL-17 pathway are mainly monospecific antibodies, which are mainly administered by subcutaneous injection

    .
    And
    Sanofi cooperation with C4X Discovery Holdings is directed to an oral small molecule drug of IL-17, on the mode of administration mAbs more advantageous
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.